References analysis of the Wikipedia article "Surrogate endpoint" in the English version

doi.org

De Gruttola, Victor G; Clax, Pamela; DeMets, David L; Downing, Gregory J; Ellenberg, Susan S; Friedman, Lawrence; Gail, Mitchell H; Prentice, Ross; Wittes, Janet; Zeger, Scott L (2001). "Considerations in the Evaluation of Surrogate Endpoints in Clinical Trials". Controlled Clinical Trials. 22 (5): 485–502. doi:10.1016/S0197-2456(01)00153-2. ISSN 0197-2456. PMID 11578783.

Cohn JN (2004). "Introduction to Surrogate Markers". Circulation. 109 (25 Suppl 1): IV20–1. doi:10.1161/01.CIR.0000133441.05780.1d. PMID 15226247.

Fleming, Thomas R. (1996). "Surrogate End Points in Clinical Trials: Are We Being Misled?". Annals of Internal Medicine. 125 (7): 605–613. doi:10.7326/0003-4819-125-7-199610010-00011. PMID 8815760. S2CID 12267404.

Prentice, Ross L. (1989). "Surrogate endpoints in clinical trials: Definition and operational criteria". Statistics in Medicine. 8 (4): 431–440. doi:10.1002/sim.4780080407. PMID 2727467.

O'Quigley, John; Flandre, Philippe (March 2006). "Quantification of the Prentice Criteria for Surrogate Endpoints". Biometrics. 62 (1): 297–300. doi:10.1111/j.1541-0420.2006.00538.x. PMID 16542258. S2CID 19927364.

Sobel, Burton E.; Furberg, Curt D. (1997). "Surrogates, Semantics, and Sensible Public Policy". Circulation. 95 (6): 1661–1663. doi:10.1161/01.CIR.95.6.1661. PMID 9118540.

Pedersen TR, Olsson AG, Faergeman O, et al. (1998). "Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S)". Circulation. 97 (15): 1453–1460. doi:10.1161/01.cir.97.15.1453. PMID 9576425.

Horton, Richard (October 25, 2003). "The statin wars: why AstraZeneca must retreat". Lancet. 362 (9393): 1341. doi:10.1016/S0140-6736(03)14669-7. PMID 14585629. S2CID 39528790.
McKillop T (November 1, 2003). "The statin wars". Lancet. 362 (9394): 1498. doi:10.1016/S0140-6736(03)14698-3. PMID 14602449. S2CID 5300990.

d'Agostino, Ralph B. (2011). "Changing End Points in Breast-Cancer Drug Approval — The Avastin Story". NEJM. 365 (2): e2. doi:10.1056/NEJMp1106984. PMID 21707384.

Lenzer, J. (2011). "FDA committee votes to withdraw bevacizumab for breast cancer". BMJ. 343: d4244. doi:10.1136/bmj.d4244. PMID 21729988. S2CID 206893438.

Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, Howard H, Swinson D, Velikova G, Anthoney A, Roy R, Seymour M (2017). "A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO)". British Journal of Cancer. 116 (4): 472–478. doi:10.1038/bjc.2016.442. PMC 5318975. PMID 28095397.

Koretz, Ronald (January 13, 2015). "Is Widespread Screening for Hepatitis C Justified?". British Medical Journal. 350: g7809. doi:10.1136/bmj.g7809. PMID 25587052. S2CID 36816304.

Ferreira PL, Ferrari-Souza JP, Tissot C, Bellaver B, Leffa D, Lussier FZ, et al. (March 2023). "Potential Utility of Plasma P-Tau and Neurofilament Light Chain as Surrogate Biomarkers for Preventive Clinical Trials". Neurology. 101 (1): 38–45. doi:10.1212/WNL.0000000000207115. PMC 10351303. PMID 36878697.

Psaty BM, Weiss NS, Furberg CD, et al. (1999). "Surrogate end points, health outcomes, and the drug approval process for the treatment of risk factors for cardiovascular disease". JAMA. 282 (8): 786–790. doi:10.1001/jama.282.8.786. PMID 10463718. S2CID 16582482.

Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O (2024). "Reporting of surrogate endpoints in randomised controlled trial reports (CONSORT-Surrogate): extension checklist with explanation and elaboration". BMJ. 386: e078524. doi:10.1136/bmj-2023-078524. PMC 11231881. PMID 38981645.

Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O (2024). "Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration". BMJ. 386: e078525. doi:10.1136/bmj-2023-078525. PMC 11231880. PMID 38981624.

nih.gov

pubmed.ncbi.nlm.nih.gov

Cohn JN (2004). "Introduction to Surrogate Markers". Circulation. 109 (25 Suppl 1): IV20–1. doi:10.1161/01.CIR.0000133441.05780.1d. PMID 15226247.

Prentice, Ross L. (1989). "Surrogate endpoints in clinical trials: Definition and operational criteria". Statistics in Medicine. 8 (4): 431–440. doi:10.1002/sim.4780080407. PMID 2727467.

Sobel, Burton E.; Furberg, Curt D. (1997). "Surrogates, Semantics, and Sensible Public Policy". Circulation. 95 (6): 1661–1663. doi:10.1161/01.CIR.95.6.1661. PMID 9118540.

d'Agostino, Ralph B. (2011). "Changing End Points in Breast-Cancer Drug Approval — The Avastin Story". NEJM. 365 (2): e2. doi:10.1056/NEJMp1106984. PMID 21707384.

Lenzer, J. (2011). "FDA committee votes to withdraw bevacizumab for breast cancer". BMJ. 343: d4244. doi:10.1136/bmj.d4244. PMID 21729988. S2CID 206893438.

Koretz, Ronald (January 13, 2015). "Is Widespread Screening for Hepatitis C Justified?". British Medical Journal. 350: g7809. doi:10.1136/bmj.g7809. PMID 25587052. S2CID 36816304.

Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O (2024). "Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration". BMJ. 386: e078525. doi:10.1136/bmj-2023-078525. PMC 11231880. PMID 38981624.

ncbi.nlm.nih.gov

Manyara AM, Davies P, Stewart D, Weir CJ, Young AE, Blazeby J, Butcher NJ, Bujkiewicz S, Chan AW, Dawoud D, Offringa M, Ouwens M, Hróbjartssson A, Amstutz A, Bertolaccini L, Bruno VD, Devane D, Faria CDCM, Gilbert PB, Harris R, Lassere M, Marinelli L, Markham S, Powers JH, Rezaei Y, Richert L, Schwendicke F, Tereshchenko LG, Thoma A, Turan A, Worrall A, Christensen R, Collins GS, Ross JS, Taylor RS, Ciani O (2024). "Reporting of surrogate endpoints in randomised controlled trial protocols (SPIRIT-Surrogate): extension checklist with explanation and elaboration". BMJ. 386: e078525. doi:10.1136/bmj-2023-078525. PMC 11231880. PMID 38981624.

worldcat.org

Surrogate endpoint (English Wikipedia)

bmj.com

crmagazine.org

doi.org

fda.gov

healio.com

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

nytimes.com

semanticscholar.org

api.semanticscholar.org

theguardian.com

unc.edu

cdr.lib.unc.edu

worldcat.org